You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 286 No. 13, October 3, 2001 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (2)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Ethical Issues in the Reporting of Clinical Trials

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: We hope the revised CONSORT statement will contribute to further improvements in the reporting of unbiased results of randomized controlled trials (RCTs).1 However, the CONSORT statement continues to neglect one of the most important aspects of the design and conduct of RCTs: the choice of an adequate control group.2 A randomized trial can adhere to all of the CONSORT statement's recommendations and yet still be biased if the investigators have selected an inferior comparator intervention for their control group.3-4 For example, it was recently shown that studies sponsored by pharmaceutical companies were judged superior or equal to studies funded by public resources for the most of the quality items incorporated in the CONSORT statement.4-5 However, these studies were potentially biased by more frequent use of a placebo/no therapy control group as a comparator. One way to ensure that an adequate control group is used lies in the . . . [Full Text of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

The CONSORT Statement: Revised Recommendations for Improving the Quality of Reports of Parallel-Group Randomized Trials
David Moher, Kenneth F. Schulz, Douglas Altman, and for the CONSORT Group
JAMA. 2001;285(15):1987-1991.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Improving the Methodologic and Ethical Validity of Best Supportive Care Studies in Oncology: Lessons From a Systematic Review
Cherny et al.
JCO 2009;27:5476-5486.
ABSTRACT | FULL TEXT  

Reporting of randomized controlled trials in Hodgkin lymphoma in biomedical journals.
Kober et al.
JNCI J Natl Cancer Inst 2006;98:620-625.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2001 American Medical Association. All Rights Reserved.